西尼莫德停药后 SARS-CoV2 感染的临床恶化。
Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.
机构信息
Department of Neurology, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Hospital Clínico San Carlos, Universidad Complutense, Madrid, Spain.
出版信息
J Med Virol. 2021 Jan;93(1):546-549. doi: 10.1002/jmv.26279. Epub 2020 Jul 15.
Abstract
The role of disease-modifying therapies in patients with autoimmune disorders during severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection is controversial. Immunocompromised patients could have a more severe coronavirus disease-2019 (COVID-19) due to the absence of an adequate immune response against the SARS-CoV-2. However, therapies that act on immune response could play a protective role by dampening the cytokine-release syndrome. Fingolimod is a drug used for immune therapy in patients with multiple sclerosis (MS) through the sequestration of activated lymphocytes in the lymph nodes. We report the case of a 57-year-old man with relapsing-remitting MS treated with fingolimod that showed a reactivation of COVID-19 with signs of hyperinflammation syndrome after fingolimod withdrawal. Our case suggests that discontinuation of fingolimod during COVID-19 could imply a worsening of SARS-CoV2 infection.
摘要
在严重急性呼吸综合征冠状病毒 2 (SARS-CoV2) 感染期间，疾病修饰疗法在自身免疫性疾病患者中的作用存在争议。由于缺乏针对 SARS-CoV-2 的充分免疫反应，免疫功能低下的患者可能会出现更严重的 2019 年冠状病毒病 (COVID-19)。然而，作用于免疫反应的疗法可以通过抑制细胞因子释放综合征发挥保护作用。芬戈莫德是一种用于多发性硬化症 (MS) 患者免疫治疗的药物，通过将活化的淋巴细胞隔离在淋巴结中。我们报告了一例使用芬戈莫德治疗的复发性缓解型多发性硬化症 57 岁男性，在停用芬戈莫德后出现 COVID-19 再激活，并伴有炎症综合征迹象。我们的病例表明，COVID-19 期间停用芬戈莫德可能意味着 SARS-CoV2 感染恶化。
相似文献
1
Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.西尼莫德停药后 SARS-CoV2 感染的临床恶化。
J Med Virol. 2021 Jan;93(1):546-549. doi: 10.1002/jmv.26279. Epub 2020 Jul 15.
2
A case of early disease rebound after fingolimod discontinuation in a patient with multiple sclerosis and SARS-CoV-2 infection.一例多发性硬化症合并 SARS-CoV-2 感染患者在停用芬戈莫德后早期疾病反弹。
Neurol Sci. 2024 Jun;45(6):2423-2426. doi: 10.1007/s10072-024-07490-z. Epub 2024 Mar 28.
3
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.多发性硬化症患者在接受芬戈莫德治疗后感染严重 COVID-19。
Mult Scler Relat Disord. 2020 Jul;42:102180. doi: 10.1016/j.msard.2020.102180. Epub 2020 May 6.
4
Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.免疫抑制多发性硬化症患者从 SARS-CoV-2 感染中康复后的免疫特征。
J Neuroimmunol. 2020 Aug 15;345:577282. doi: 10.1016/j.jneuroim.2020.577282. Epub 2020 May 29.
5
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.接受免疫抑制剂治疗的多发性硬化症患者：在整个新冠疫情范围内。
Rev Neurol (Paris). 2020 Jun;176(6):523-525. doi: 10.1016/j.neurol.2020.04.009. Epub 2020 Apr 27.
6
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.微妙的平衡：免疫抑制与免疫疗法在多发性硬化合并 COVID-19 患者中的应用。
Mult Scler Relat Disord. 2020 Jul;42:102182. doi: 10.1016/j.msard.2020.102182. Epub 2020 May 8.
7
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.多发性硬化症患者感染 COVID-19 的风险：一项病例对照研究。
Neurol Neuroimmunol Neuroinflamm. 2022 Jan 19;9(2). doi: 10.1212/NXI.0000000000001141. Print 2022 Mar.
8
Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.从芬戈莫德转换为富马酸二甲酯的多发性硬化症患者疾病活动度增加：病例系列研究。
BMC Neurol. 2021 Feb 2;21(1):48. doi: 10.1186/s12883-021-02058-2.
9
Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.盐酸芬戈莫德用于治疗复发缓解型多发性硬化症。
Expert Opin Pharmacother. 2017 Oct;18(15):1649-1660. doi: 10.1080/14656566.2017.1373093. Epub 2017 Sep 4.
10
Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia.在新冠疫情时代管理多发性硬化症：沙特阿拉伯专家小组对文献的回顾和共识报告。
Mult Scler Relat Disord. 2021 Jun;51:102925. doi: 10.1016/j.msard.2021.102925. Epub 2021 Mar 25.
引用本文的文献
1
Clinical Outcomes of Hospitalized Immunocompromised Patients With COVID-19 and the Impact of Hyperinflammation: A Retrospective Cohort Study.COVID-19免疫功能低下住院患者的临床结局及高炎症反应的影响：一项回顾性队列研究
J Inflamm Res. 2025 Mar 7;18:3385-3397. doi: 10.2147/JIR.S482940. eCollection 2025.
2
The Sphingolipid-Signaling Pathway as a Modulator of Infection by SARS-CoV-2.鞘脂信号通路作为新冠病毒感染的调节剂
Curr Issues Mol Biol. 2023 Sep 28;45(10):7956-7973. doi: 10.3390/cimb45100503.
3
Knowledge mapping of COVID-19 and autoimmune diseases: a visual and bibliometric analysis.COVID-19 与自身免疫性疾病的知识图谱：可视化与文献计量分析。
Clin Exp Med. 2023 Nov;23(7):3549-3564. doi: 10.1007/s10238-023-01089-y. Epub 2023 Jul 3.
4
Potential treatments of COVID-19: Drug repurposing and therapeutic interventions.COVID-19 的潜在治疗方法：药物再利用和治疗干预。
J Pharmacol Sci. 2023 May;152(1):1-21. doi: 10.1016/j.jphs.2023.02.004. Epub 2023 Feb 15.
5
Will Omics Biotechnologies Save Us from Future Pandemics? Lessons from COVID-19 for Vaccinomics and Adversomics.组学生物技术能将我们从未来的大流行中拯救出来吗？新冠疫情给疫苗组学和药物不良事件组学带来的启示。
Biomedicines. 2022 Dec 26;11(1):52. doi: 10.3390/biomedicines11010052.
6
The effect of Fingolimod on patients with moderate to severe COVID-19.芬戈莫德对中重度 COVID-19 患者的影响。
Pharmacol Res Perspect. 2023 Feb;11(1):e01039. doi: 10.1002/prp2.1039.
7
Prognostic markers for the clinical course in the blood of patients with SARS-CoV-2 infection.SARS-CoV-2 感染患者血液中临床病程的预后标志物。
Eur J Med Res. 2022 Nov 21;27(1):255. doi: 10.1186/s40001-022-00864-z.
8
Computational pharmacology: New avenues for COVID-19 therapeutics search and better preparedness for future pandemic crises.计算药理学：寻找 COVID-19 治疗方法的新途径，为未来的大流行危机做好更好的准备。
Biophys Chem. 2022 Nov;290:106891. doi: 10.1016/j.bpc.2022.106891. Epub 2022 Sep 11.
9
Potential role of marine species-derived bioactive agents in the management of SARS-CoV-2 infection.海洋物种来源的生物活性物质在管理 SARS-CoV-2 感染中的潜在作用。
Future Microbiol. 2021 Nov;16(16):1289-1301. doi: 10.2217/fmb-2021-0024. Epub 2021 Oct 25.
10
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.多发性硬化症、疾病修正疗法与2019冠状病毒病：关于免疫反应和疫苗接种建议的系统综述
Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.
本文引用的文献
1
Dexamethasone in the management of covid -19.地塞米松在新冠病毒病治疗中的应用
BMJ. 2020 Jul 3;370:m2648. doi: 10.1136/bmj.m2648.
2
Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab.使用阿仑单抗治疗的严重多发性硬化症患者潜在的 COVID-19 感染。
Mult Scler Relat Disord. 2020 Sep;44:102297. doi: 10.1016/j.msard.2020.102297. Epub 2020 Jun 11.
3
Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.免疫抑制多发性硬化症患者从 SARS-CoV-2 感染中康复后的免疫特征。
J Neuroimmunol. 2020 Aug 15;345:577282. doi: 10.1016/j.jneuroim.2020.577282. Epub 2020 May 29.
4
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.与 COVID-19 大流行期间多发性硬化症疾病修正治疗相关的基础生物学。
Mult Scler Relat Disord. 2020 Aug;43:102174. doi: 10.1016/j.msard.2020.102174. Epub 2020 May 12.
5
COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.COVID-19：考虑使用白细胞介素 6 受体拮抗剂治疗 SARS-CoV-2 感染患者的细胞因子风暴综合征。
J Med Virol. 2020 Nov;92(11):2260-2262. doi: 10.1002/jmv.26078. Epub 2020 Jun 19.
6
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.微妙的平衡：免疫抑制与免疫疗法在多发性硬化合并 COVID-19 患者中的应用。
Mult Scler Relat Disord. 2020 Jul;42:102182. doi: 10.1016/j.msard.2020.102182. Epub 2020 May 8.
7
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.多发性硬化症患者在接受芬戈莫德治疗后感染严重 COVID-19。
Mult Scler Relat Disord. 2020 Jul;42:102180. doi: 10.1016/j.msard.2020.102180. Epub 2020 May 6.
8
Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain.多发性硬化症及相关疾病中的抗CD20与COVID-19：来自西班牙马德里的60例患者病例系列
Mult Scler Relat Disord. 2020 Jul;42:102185. doi: 10.1016/j.msard.2020.102185. Epub 2020 May 7.
9
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.一名接受芬戈莫德治疗的多发性硬化症患者感染了新冠病毒。
Neurol Neuroimmunol Neuroinflamm. 2020 May 5;7(4). doi: 10.1212/NXI.0000000000000753. Print 2020 Jul.
10
Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19.抗CD20免疫抑制疾病改善疗法与新型冠状病毒肺炎
Mult Scler Relat Disord. 2020 Jun;41:102135. doi: 10.1016/j.msard.2020.102135. Epub 2020 Apr 18.
Zotero 插件